OBJECTIVES

This study describes the cost during hospitalization, LOS, readmission and quality of life (QoL) among Chinese patients received the ATTUNE^® Knee system in primary TKA in China ATTUNE^® study (ClinicalTrials.gov Identifier: NCT03542045).

METHODS

China ATTUNE^® study is a prospective, single arm, non-randomized, 4-center observational study on primary TKA. The eligible patients were involved for the analysis after TKA until December 25th, 2019. Descriptive analysis was performed to understand the total cost of hospitalization in RMB, LOS in days, readmission rate and readmission cost. Sign test or Wilcoxon Signed Rank Test was performed to compare repeated measurements of EQ5D-5L at baseline and follow-up period.

RESULTS

At cutoff date, a total of 119 patients were enrolled. 115 eligible patients (16.5% male; age: 63.3 +/- 6.77 years) were included in this analysis with average 7.07 (1.11-17.48) month follow-up period. The total cost of hospitalization was ¥83 645.9 +/- 28 151.05. The average cost of medicine, procedure service, implant, disposables, examination and other medical cost was ¥5447.6+/-2 872, ¥7180.4 +/- 1 754.1, ¥72750.4 +/- 82 844.2, ¥2680.1 +/- 1516.8, ¥5360.0 +/-1977.1, ¥3433.6 +/- 2180.8 respectively. The intra-operative complication rate was 2.6% (3/115). The average LOS was 9.3 (± 2.98) days. All patients were discharged to home/caregivers. During the follow-up period, no readmission was observed. Provisional results showed that compared to pre-op baseline (0.50 +/- 0.18), significant improvement was observed in EQ5D-5L index at 6 week (0.60 +/- 0.13), 6 month (0.70 +/- 0.12) and 1 year (0.80 +/- 0.17) (p < 0.001), as well as the improvement in self-rated health status measured by EQ-VAS (P<0.0001).

CONCLUSIONS

Compared with existing clinical pathway of China ministry of health on average LOS of TKA (14-20 days), ATTUNE^® Knee system showed shorter LOS and could reduce related hospitalization cost while maintaining quality care and improve long-term QoL of patients.